Questions? Call us at 800-810-7790
Are you overpaying for FARXIGA®?

Consider BRENZAVVY® (bexagliflozin)

An Affordable SGLT2 Inhibitor. Marley Drug offers 30 BRENZAVVY (bexaglifozin) tablets for just $59.95/month.

BRENZAVVY is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. BRENZAVVY is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.

BRENZAVVY and FARXIGA are both part of a drug class called SGLT2 Inhibitors

Several SGLT2 inhibitors, such as Farxiga and BRENZAVVY, are currently on the market for treating type 2 diabetes. These medications helps your kidneys get rid of more sugar in your urine by blocking a specific molecule called SGLT2 in the kidney tubes that usually reabsorbs sugar. By blocking this molecule this helps to promote the excretion of glucose in the urine.

Despite their effectiveness, the steep retail prices of these medications often place them beyond the financial means of those in need.

BRENZAVVY costs up to 90% less than Farxiga - just $59.95/month

BRENZAVVY and Farxiga have been studied in a head-to-head study.
Compare BRENZAVVY vs. Farxiga

Please refer to Important Safety Information below or the full Prescribing Information.


BRENZAVVY is proven effective for glycemic control in randomized, controlled clinical trials for adults with type 2 diabetes. Approved in January 2023 for type 2 diabetes in adults, BRENZAVVY, when coupled with a well-balanced diet and regular exercise, can significantly enhance your glycemic control and A1C levels.

  • Clinically proven to lower A1C
  • Taken by mouth, once daily
  • Can be taken in the morning with or without food

Please note that BRENZAVVY is not recommended for reducing blood sugar in patients with type 1 diabetes.

The most common side effects of BRENZAVVY include:

  • vaginal yeast infections
  • urinary tract infection
  • changes in urination including an urgent need to urinate more often, in larger amounts, or at night.

Please refer to Important Safety Information below or the full Prescribing Information.

Call 800-810-7790 to learn more

Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

BRENZAVVY may affect the way other medicines work, and other medicines may affect how BRENZAVVY works. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

Please refer to Prescribing Information or Important Safety Information below.

Why Is Our BRENZAVVY Price So Competitive?

Brenzavvy is available through Marley Drug thanks to a partnership with the manufacturer. The manufacturer and Marley Drug share the goal of providing broader access to drugs at a low cost. Through this agreement we can offer this medication at a much lower price than other medications in its class by bypassing wholesalers and insurance middlemen (which contribute to the high cost of medications). Because of this, Brenzavvy is not available at local pharmacies.

Accessing BRENZAVVY at $59.95 per month* is hassle-free, without the need for insurance. We're able to offer this remarkable price through our partnership with TheracosBio, the manufacturer.

  • No insurance required
  • Nationwide free shipping
  • Available to all patients*

Don't let the high cost of essential medications stand in your way. Choose BRENZAVVY and experience relief without breaking the bank.

*With a valid prescription.

Don't have a prescription yet?

Download the form below to take to your next appointment. It will outline for your healthcare provider what Brenzavvy is and how to prescribe to Marley Drug.

Download Information Sheet


Order online or over the phone

If you run into issues, just give us a call at 800-810-7790.

We will verify your prescription

We can contact your doctor for the prescription.

We will ship it to your home

We offer free shipping through USPS First Class Mail to all 50 states. Our average delivery time is 2 days.

Hear from our Customers

I really love Marley’s quick responses and the fact that I can purchase a 6 month supply rather than running to the drugstore every 30/90 days. The staff is wonderful, helpful and knowledgeable. I love ...
Read More
Patty S.
The Wholesale Price List made my prescription easy to afford, I was about to cancel my prescription because my monthly cost with insurance was almost $150! Now I can get a 6-month supply for only $37 ...
Read More
Mark T.
Check out this mail in pharmacy. My cardiologist referred me to them for best price on cholesterol lowering med. I found them to be helpful, professional and provide prompt service.
Theresa S.
As soon as my doctor submitted the prescription, I was contacted by Terri, who explained the process and set up delivery to my home. It could not have been easier!
Amy W.
Stock photos are used to represent actual testimonials of Marley Drug customers.

Have medication questions?
Talk with a pharmacist today.

Call us for a free pharmacy consult.


Most commonly asked questions about BRENZAVVY


Limitation of Use: BRENZAVVY (bexagliflozin) is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients.

BRENZAVVY is contraindicated in patients with hypersensitivity to bexagliflozin or any excipient in BRENZAVVY. Anaphylaxis and angioedema have been reported with sodium-glucose co-transporter 2 (SGLT2) inhibitors.

Warnings and Precautions

Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis
BRENZAVVY increases the risk of life-threatening ketoacidosis in patients with type 1 diabetes. Type 2 diabetes and pancreatic disorders are also risk factors for ketoacidosis and fatal events of ketoacidosis have been reported in patients with type 2 diabetes using SGLT2 inhibitors. Precipitating conditions for diabetic ketoacidosis or other ketoacidosis include under-insulinization due to insulin dose reduction or missed insulin doses, acute febrile illness, reduced caloric intake, ketogenic diet, surgery, volume depletion, and alcohol abuse. Signs and symptoms of diabetic ketoacidosis are consistent with dehydration and severe metabolic acidosis and include nausea, vomiting, abdominal pain, generalized malaise, and shortness of breath. Assess patients who present with signs and symptoms of metabolic ketoacidosis, regardless of blood glucose levels. If suspected, discontinue BRENZAVVY, treat promptly and monitor for resolution before restarting. Consider ketone monitoring in patients with type 1 diabetes mellitus as well as in others at risk for ketoacidosis. Withhold BRENZAVVY in clinical situations known to predispose to ketoacidosis and resume when clinically stable. Educate all patients on the signs and symptoms of ketoacidosis and instruct patients to discontinue BRENZAVVY and seek medical attention immediately if signs and symptoms occur.

Lower Limb Amputation
Lower limb amputations have been observed in patients treated with BRENZAVVY in a study of patients with type 2 diabetes who had either established cardiovascular disease (CVD) or were at risk for CVD. Of the 23 BRENZAVVY-treated patients who had amputations, 15 were amputations of the toe and midfoot and 8 were amputations above and below the knee. Some patients had multiple amputations. Lower limb infections, gangrene, ischemia, and osteomyelitis were the most common precipitating medical events leading to the need for an amputation. The risk of amputation was highest in patients with a baseline history of prior amputation, peripheral vascular disease, and neuropathy.

Before initiating BRENZAVVY, consider factors in the patient’s history that may predispose to the need for amputations, such as a history of prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers. Counsel patients receiving BRENZAVVY about the importance of routine preventative foot care and monitor for signs and symptoms of diabetic foot infection (including osteomyelitis), new pain or tenderness, sores or ulcers involving the lower limbs, and institute appropriate treatment.

Volume Depletion
BRENZAVVY can cause intravascular volume contraction which may sometimes manifest as symptomatic hypotension or acute transient changes in creatinine. Acute kidney injury requiring hospitalization and dialysis has been reported in patients with type 2 diabetes receiving SGLT2 inhibitors. Before initiating, assess volume status and renal function in patients with impaired renal function (eGFR less than 60 mL/min/1.73 m2), elderly patients, patients with low systolic blood pressure, or patients on loop diuretics. In patients with volume depletion, correct this condition. After initiating, monitor for signs and symptoms of volume depletion and renal function.

Urosepsis and Pyelonephritis
Serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization have been identified in patients receiving SGLT2 inhibitors, including BRENZAVVY. Treatment with BRENZAVVY increases the risk for urinary tract infections. Evaluate patients for signs and symptoms of urinary tract infections and treat them promptly.

Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues
Insulin and insulin secretagogues (e.g., sulfonylureas) are known to cause hypoglycemia. BRENZAVVY may increase the risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. A lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with BRENZAVVY.

Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene)
Serious, life-threatening cases requiring urgent surgical intervention have been identified in postmarketing surveillance in both males and females with diabetes mellitus receiving SGLT2 inhibitors. Serious outcomes have included hospitalization, multiple surgeries, and death. Assess patients presenting with pain or tenderness, erythema, or swelling in the genital or perineal areas, along with fever or malaise. If suspected, start treatment, and discontinue BRENZAVVY.

Genital Mycotic Infections
RENZAVVY increases the risk of genital mycotic infections. Patients who have a history of genital mycotic infections or who are uncircumcised are more likely to develop genital mycotic infections. Monitor and treat appropriately.

MOST COMMON ADVERSE REACTIONS (>5%): Female genital mycotic infections, urinary tract infection and increased urination.


  • Pregnancy: BRENZAVVY is not recommended during the second and third trimesters.
  • Lactation: BRENZAVVY is not recommended when breastfeeding.
  • Geriatric patients: There is a higher incidence of adverse reactions related to volume depletion.
  • Renal Impairment: There is a higher incidence of adverse reactions related to reduced renal function.
  • Hepatic Impairment: BRENZAVVY is not recommended for patients with severe hepatic impairment.

Inducers of UGT1A9 could result in more rapid clearance of BRENZAVVY by metabolism. Doses of insulin and sulfonylureas may need to be reduced to offset the action of BRENZAVVY. The safety of BRENZAVVY is compromised when it is coupled with insulin or an insulin secretagogue (sulfonylureas and meglitinides – the latter rarely used in the US). Lithium carbonate is used as a mood stabilizer in bipolar disorder. Lithium ions might be preferentially (compared to sodium ions) taken up with glucose in the kidney. Empirical evidence has shown that lithium levels can be lower when SGLT2 inhibitors are administered. SGLT2 inhibitors produce pronounced glucosuria, which makes urine testing for glucose diagnostically useless. Measurements of 1,5 anhydroglucitol are also compromised.

For additional important safety information about BRENZAVVY, please see the full Prescribing Information.

All trademarks, registered or otherwise, are the property of their respective owner(s).